Medindia

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases and highly specialized conditions, will present data assessing primary immunodeficiency (PI) patient treatment satisfaction with ...
Medindia

Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting

Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment infusion volume and rates Shire plc (LSE: SHP, ...
Monthly Prescribing Reference

Cuvitru Approved for Primary Immunodeficiency

Shire announced that the Food and Drug Administration (FDA) has approved Cuvitru (immune globulin subcutaneous [human]) 20% solution for the treatment of primary immunodeficiency in patients aged ≥2 ...
PR Newswire

Shire Announces U.S. FDA Approval of CUVITRUTM [Immune Globulin Subcutaneous (Human), 20% Solution] Treatment for Primary Immunodeficiency

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Shire plc (LSE: SHP; NASDAQ: SHPG) announced that the United ...